Deloof S, Montel V, Chatelain A. Effects of rat corticotrophin-releasing factor, arginine vasopressin and oxytocin on the secretions of adrenocorticotrophic hormone and corticosterone in the fetal rat in late gestation: in vivo and in vitro studies. Eur (11) and, given together, these two peptides present a synergistic interaction on ACTH secretion (12). In the fetal baboon, the infusion of rCRF increases plasma ACTH concentration but not cortisol (13); in vitro, rCRF is a potent stimulus of ACTH release by human fetal pituitaries (14).
It is well established that the activity of the pituitaryadrenal axis is regulated by several peptides, including rat corticotrophin-releasing factor (rCRF), arginine vasopressin (AVP) and oxytocin (OT), which are found in high concentrations in the pituitary portal blood of the adult rat (1) .
In the adult rat, rCRF, which is the most potent of these peptides, increased ACTH secretion in vivo (2) and in vitro (3) . A number of in vivo (4) and in vitro (5, 6) studies have shown that AVP weakly stimulates ACTH release and potentiates the ACTH response to rCRF. In addition to AVP, OT also stimulates weakly ACTH release in vivo (7) and in vitro (8) but potentiates the rCRF-stimulated ACTH release both in vivo and in vitro (9, 10) .
As far as fetuses are concerned, most results are related to fetal ovine. Indeed, many in vivo studies have shown that rCRF or AVP given alone increase the plasma concentration of ACTH and glucocorticoids (11) and, given together, these two peptides present a synergistic interaction on ACTH secretion (12) . In the fetal baboon, the infusion of rCRF increases plasma ACTH concentration but not cortisol (13) ; in vitro, rCRF is a potent stimulus of ACTH release by human fetal pituitaries (14) .
In the fetal rat at term, the presence of immuno¬ reactive rCRF, AVP or OT detected in the hypothalamus and pituitary gland (15, 16) 4 and 92 pmol/0.5 ml (Fig. 1) . These (Fig. 2a) . At 
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Peptides (pmol/0.5 ml) ( Fig. 2b ) and these peptides alone or in combination did not induce any significant change in plasma cortico¬ sterone concentration compared to injected fetuses with saline (p> 0.05) (Fig. 2b) .
At the end of the sampling period the injection of saline increased the plasma corticosterone concentra¬ tion slightly and it was not significantly different from that of uninjected fetuses (p>0.05) (Fig. 2b) . Oxytocin did not modify the plasma corticosterone concentration compared to that of injected fetuses with saline (p>0.05) (Fig. 2b) . The injection of rCRF or AVP alone or rCRF in combination with AVP or OT increased the plasma corticosterone concentration compared to saline injection (p < 0.05-p< 0.001) (Fig. 2b) and uninjected fetuses (p<0.01-p<0.001) (Fig. 2b) . Arginine vaso¬ pressin or OT did not potentiate a corticosterone re¬ sponse to rCRF (p>0.05) (Fig. 2b) .
In vitro study
The production of ACTH by perifused fetal anterior lobes was stimulated by rCRF (Fig. 3) . Arginine vasopressin and OT had a weak stimulating effect on ACTH release compared to rCRF (Fig. 3) . The average ACTH release (area under the curve) showed that AVP and OT potentiated the effect of rCRF on ACTH release (insets in Fig. 3) .
Discussion
The present study shows that a bolus injection of saline into the umbilical vein of 21-day-old rat fetuses de¬ creases ACTH secretion during the first 10 min. This result contrasts with data reported by most investiga¬ tors, who have shown that ACTH secretion was not modified significantly after intravenous saline injection in many species such as sheep (19) , rats (20) , monkeys (21), men (22) , fetal and neonatal sheep (11, 12 (24) and ovine fetuses (2 5) . in the rat, ANF was found to inhibit ACTH secretion in vivo ( 2 6 ) and to inhibit in vitro cultured anterior pituitary cells stimulated by CRF (27) but had no effect on in vitro corticosterone secretion from isolated adrenal cells (28, 29) . Moreover, the apparent short half-life of ANF in rat blood (30) (27) . In the fetal rat, immunological studies have revealed the presence of immunoreactive ANF in both atrial and ventricular cardiocytes (31) and in the blood circulation (32 
